<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0909245876
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2005
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VALIUM AMP 10MG-2ML
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DIAZEPAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Controlled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        23.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="CENEXI" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            CENEXI
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Atnahs Pharma UK Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05BA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Valium is:<br />Valium Ampoules, 10 mg/2 ml: clear injection solution containing 10 mg diazepam per 2<br />ml.<br />What it is used for:<br />Basic sedation prior to stressful therapeutic measures or procedures such as endoscopy,<br />external electrical shock defibrillation, cardiac catheterization, radiological investigations,<br />minor surgery, reduction of dislocations and fractures, biopsies, dressing changes in burns</p><p>patients, etc. in order to alleviate anxiety or acute stress reactions and to aid post-<br />procedure amnesia.</p><p>Preoperative medication in anxious and tense patients.<br />Indications in psychiatry<br />Treatment of agitation associated with acute anxiety states and panic attacks, motor<br />restlessness and delirium tremens.<br />Anticonvulsant action<br />Treatment of status epilepticus and other convulsive states (including tetanus).<br />Gynecology/obstetrics<br />Treatment of eclampsia, facilitation of delivery in carefully selected cases.</p><p>&nbsp;</p><p><br />As adjuvant therapy to relieve reflex muscle spasms associated with local trauma<br />(wounds, inflammation) and to combat spasticity associated with damage to spinal and<br />supraspinal interneurons; such changes can occur, for example, in spasms of cerebral<br />origin, paraplegia, athetosis, and the stiff-man syndrome.<br />How Valium works<br />The active ingredient of Valium is a member of the benzodiazepine group of<br />tranquilizers, which possess anxiolytic, sedative, muscle-relaxant, and anticonvulsant<br />properties. These actions are now known to be due to potentiation of the effect of<br />&gamma;-aminobutyric</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You must not be given Valium if:<br />Known hypersensitivity to benzodiazepines or to any excipient listed under Composition.<br />Severe respiratory failure, severe liver failure, sleep apnea syndrome and myasthenia<br />gravis.<br />Benzodiazepines are not recommended for the primary treatment of psychotic disorders.<br />Benzodiazepines should not be used for the treatment of depression or anxiety states<br />related to depression, as such patients are at risk of suicide.<br />Warnings and Precautions for use<br />Simultaneous use of alcohol/central nervous system depressants<br />Simultaneous use of Valium and alcohol or other central nervous system depressants<br />should be avoided. Such simultaneous use may potentiate the clinical effect of Valium<br />with possible consequences such as severe sedation or clinically relevant respiratory<br />and/or cardiovascular depression (see Interactions).<br />History of alcohol or medication abuse<br />Valium should only be used with extreme caution in patients with a prior diagnosis of<br />alcohol, medication or recreational drug abuse. Use of Valium should be avoided in<br />patients dependent on central nervous system depressants, including alcohol.<br />The exception to the above is the management of acute withdrawal symptoms. The<br />patient should be warned against simultaneous consumption of alcohol as such a<br />combination can potentiate the undesirable effects of both substances.<br />Lower doses should be used in elderly or debilitated patients. Particular caution is<br />essential when injecting Valium intravenously. Apnea or cardiac arrest have been<br />reported in particular in elderly and severely ill patients and in patients with cardiac or<br />respiratory failure.</p><p>The benzyl alcohol contained in Valium ampoules may cause irreversible damage in<br />neonates and in particular in premature neonates. For this reason, ampoules should only<br />be used in these patients if there is no alternative treatment.<br />Caution is required in known cardiorespiratory failure as sedatives such as Valium can<br />exacerbate pre-existing respiratory depression. On the other hand, the sedative effect can<br />be beneficial in some patients in that it reduces the effort required for breathing.<br />Very small veins should not be used for injection. In particular, intra-arterial injection and<br />extravasation should be avoided at all costs, as rapid intravenous injection in particular<br />can lead to venous thrombosis, phlebitis, local irritation, swelling or &ndash; more rarely &ndash;<br />vascular changes.<br />When treating patients with impaired renal or hepatic function the standard precautionary<br />measures should be followed.<br />Rebound anxiety<br />Rebound anxiety refers to a transient syndrome in which the symptoms that led to<br />treatment with Valium in the first place recur with increased intensity. This can occur on<br />discontinuation of treatment. This syndrome can also be accompanied by other reactions<br />such as mood changes, anxiety, and restlessness.<br />As the risk of withdrawal symptoms and rebound phenomena is greater after abrupt<br />discontinuation of treatment, it is recommended that the dose be reduced gradually.<br />Amnesia<br />It is important to bear in mind that benzodiazepines can cause anterograde amnesia. This<br />form of amnesia can also occur at therapeutic doses, the risk increasing with increasing<br />dose. The amnesic effects can be accompanied by odd behaviour.<br />Psychiatric and &ldquo;paradoxical&rdquo; reactions<br />It is known that benzodiazepine administration can cause paradoxical reactions such as<br />agitation, irritability, aggressiveness, delusions, outbursts of rage, nightmares,<br />hallucinations, psychoses, odd behavior, and other behavioral disturbances. In such cases<br />administration of the drug should be discontinued. Such reactions are more common in<br />children and elderly patients.<br />Tolerance<br />Response to the effect of benzodiazepines may weaken after repeated Valium use over a<br />prolonged period.<br />Children and neonates<br />The safety and efficacy of Valium have not been studied in children under 6 months of<br />age. Valium should be used in this age group only with the greatest caution and in the<br />absence of alternative treatments.</p><p>Dependence<br />The use of benzodiazepines may cause physical and psychological dependence. This risk<br />is increased by prolonged use and high doses and in patients with known alcohol and/or<br />drug abuse. Withdrawal phenomena occur especially after abrupt treatment<br />discontinuation and are limited in milder cases to tremor, agitation, sleep disturbance,<br />anxiety, headache, and impairment of concentration. However, other symptoms such as<br />sweating, muscle and abdominal cramps, perceptual disturbances and, in rare cases,<br />delirium and convulsions may occur.<br />Depending on the duration of action of the substance, withdrawal phenomena appear a<br />few hours to a week or even more after discontinuation of treatment.<br />In order to minimize the risk of dependence, benzodiazepines should be prescribed only<br />after a careful consideration of the indication and should be taken for as short a period as<br />possible (generally no longer than four weeks when used as a hypnotic, for example). The<br />need for continuation of treatment should be reviewed regularly. More prolonged<br />treatment is indicated only in certain patients (for example with panic attacks) and its<br />benefit compared to the risks is less clear.<br />In order to avoid withdrawal symptoms, treatment should be discontinued by tapering the<br />dose in all patients. Should withdrawal symptoms occur nonetheless, close medical<br />monitoring and support of the patient are required.<br />Interaction with other medicinal products and other forms of interaction<br />Pharmacokinetic interactions (drug-drug interactions (DDI)):<br />Oxidative metabolism of diazepam leading to the formation of N-desmethyldiazepam,<br />3-hydroxydiazepam (temazepam) and oxazepam depends on the CYP2C19 and CYP3A<br />isoenzymes of cytochrome P450. In-vitro studies have shown that the CYP3A isoform is<br />mainly responsible for hydroxylation while both CYP3A and CYP2C19 are responsible<br />for N-demethylation. The results of in-vivo studies conducted in volunteers have<br />confirmed the in-vitro results. Substrates modulating CYP3A and/or CYP2C19 may<br />influence the pharmacokinetics of diazepam. Inhibitors of CYP3A and CYP2C19 such as<br />cimetidine, ketoconazole, fluvoxamine, topiramate, fluoxetine and omeprazole may<br />produce more potent and longer sedation. In addition, diazepam has been reported to<br />modify the metabolic elimination of phenytoin.<br />Pharmacodynamic interactions (DDI)<br />The effects on sedation, respiration and hemodynamics may be potentiated when taking<br />Valium with central depressants such as neuroleptics, anxiolytics/sedatives,<br />antidepressants, hypnotics, anticonvulsants, narcotic analgesics, anesthetics and sedative<br />antihistamines or with alcohol.<br />Patients receiving Valium should avoid taking alcohol (see Warnings and precautions).<br />For additional remarks on other central depressants, including alcohol, see Overdosage.<br />Theophylline may inhibit the action of diazepam.</p><p>On the other hand, no interactions with commonly used antidiabetic agents,<br />anticoagulants or diuretics are known.<br />Rifampicin is a potent hepatic enzyme inducer. This may accelerate diazepam metabolism<br />in the liver.<br />When Valium is given in combination with opiates that cause respiratory depression, the<br />possibility of potentiation of the respiratory depressant effect should be borne in mind.<br />Pregnancy<br />Valium should not be used during pregnancy unless it is clearly required.<br />Diazepam and its metabolites cross the placenta.<br />Prolonged administration of benzodiazepines during pregnancy can result in hypotension,<br />respiratory failure, and hypothermia in the neonate. With this category of drugs,<br />withdrawal phenomena have also been reported occasionally in neonates. Particular<br />caution is required when Valium is used during labour and delivery, as high individual<br />doses can cause irregularities of heart rate in the unborn child and hypotonia, poor<br />sucking, hypothermia, and moderately severe respiratory depression in the neonate<br />(floppy infant syndrome). It must be borne in mind that the enzyme system responsible<br />for the degradation of diazepam is not yet fully developed in neonates (especially<br />premature neonates).<br />Lactation<br />Diazepam and its metabolites are excreted in breast milk. Where use of Valium is clearly<br />necessary during lactation, breast-feeding should be discontinued.<br />Effects on ability to drive and use machines<br />Valium has a pronounced influence on the ability to drive and use machines. Patients<br />taking Valium should be warned against performing activities that require full mental<br />alertness; these include the operation of dangerous machines and the driving of motor<br />vehicles. Patients taking Valium should also be warned against simultaneous<br />consumption of alcoholic beverages, as such a combination can potentiate the undesirable<br />effects of both types of substances.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Parenteral administration<br />If need be, in acute or critical situations or where the response to oral administration is<br />inadequate, higher doses should be given parenterally.<br />The parenteral doses generally recommended in adults and adolescents range from 2 to<br />20 mg i.m. or i.v. depending on body weight, indication and the severity of the symptoms<br />being treated. In certain indications (e.g. tetanus) higher doses may be required.</p><p>Intravenous injection of Valium should be slow (approx. 0.5-1 ml per minute) since over-<br />rapid administration can cause apnea. Ready-to-use resuscitation equipment should</p><p>always be at hand.</p><p>Special dosage instructions<br />Ampoules<br />There is evidence that diazepam can be adsorbed within plastic infusion bags and<br />infusion sets containing PVC and leading to a reduction in diazepam concentration by<br />50% or more, especially where prepared bags are stored for 24 hours or more, in warm</p><p>ambient conditions, or where long tubing sets or slow rates of infusion are used. PVC-<br />containing bags and infusion sets should be avoided when infusing diazepam. When</p><p>infusing diazepam, caution should be exercised when switching between PVC and non-<br />PVC-containing bags and infusion sets.</p><p>Neonates<br />Ampoules should be used in these patients only in the absence of alternative treatment<br />(see Warnings and precautions).<br />Anesthesiology<br />Premedication: 10-20 mg (children: 0.1-0.2 mg per kg body weight) i.m. one hour before<br />induction of anesthesia.<br />Induction of anesthesia: 0.2-0.5 mg per kg body weight i.v.<br />Basic sedation before stressful procedures and investigations: 10-30 mg (children: 0.1-<br />0.2 mg per kg body weight) i.v.<br />The best method for adjusting the dosage in each patient is to give an initial injection of<br />5 mg = 1 ml (or 0.1 mg per kg body weight) followed by the injection of repeated doses<br />of 2.5 mg (or 0.05 mg per kg body weight) at 30-second intervals until closure of the<br />eyelids.<br />Gynecology and obstetrics<br />Eclampsia: for current or impending seizures, inject 10&ndash;20 mg i.v., then further doses as<br />required i.v. or by continuous drip infusion (up to 100 mg in 24 hours).<br />Facilitation of delivery: 10&ndash;20 mg i.m. (in severe agitation, possibly i.v.) when the cervix<br />is 2&ndash;5 cm dilated. Injection of 10&ndash;20 mg i.v. facilitates obstetric interventions and<br />suturing of episiotomy wounds.<br />Tetanus<br />0.1-0.3 mg per kg body weight by i.v. injection at intervals of 1-4 hours or continuous<br />drip infusion (3-4 mg per kg body weight within 24 hours); the same dose can also be<br />administered simultaneously by nasoduodenal tube.<br />Status epilepticus<br />0.15-0.25 mg per kg body weight i.v., repeated if necessary after 10-15 minutes, possibly<br />by continuous drip infusion (maximum dose: 3 mg per kg body weight in 24 hours).</p><p>Agitation<br />Acute anxiety states, motor restlessness, delirium tremens: initially inject 0.1-0.2 mg per<br />kg body weight i.v.; repeat at 8-hour intervals until subsidence of acute symptoms, then<br />continue treatment orally.<br />All dosage forms<br />Elderly patients and patients with hepatic impairment should receive a lower dose. These<br />patients should be checked regularly at the start of treatment so that if necessary the dose<br />can be reduced and/or the dosage interval prolonged in order to avoid overdosage as a<br />result of product accumulation.<br />After about one week of treatment, consideration should be given to reducing the dose.</p><p>Duration of treatment<br />The duration of treatment should be as short as possible. The patient should be reassessed<br />at regular intervals and the need for continued treatment determined, especially if the<br />patient no longer has any symptoms. The duration of treatment &ndash; the tapering-off period<br />included &ndash; should not exceed two to three months. More prolonged treatment should be<br />contemplated only after a reassessment of the situation. At the start of treatment, it may<br />be useful to inform the patient that the duration of treatment will be limited and to explain<br />in detail how the dose will be tapered off.<br />It is also important to inform the patient of the possibility of rebound phenomena so that<br />he/she will not be too worried should these occur. There is evidence that with short-acting<br />benzodiazepines, withdrawal phenomena can occur even within the dose interval,<br />especially with high doses. When long-acting benzodiazepines such as diazepam are<br />used, it is mandatory to warn the patient against switching to a short-acting<br />benzodiazepine, as this can result in withdrawal phenomena.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The most frequently reported undesirable effects are fatigue, drowsiness and muscle<br />weakness; they are normally dose-related. These reactions occur mainly on starting<br />treatment and generally resolve on prolonged use.<br />Blood and lymphatic system<br />Elevation of alkaline phosphatase blood levels during i.v. administration.<br />Psychiatric disorders<br />Experience shows that paradoxical reactions such as restlessness, agitation, irritability,<br />aggressiveness, delusions, anger, nightmares, hallucinations, psychoses, odd behavior and<br />other undesirable behavioural effects can occur with use of benzodiazepines. In such<br />cases the drug should be discontinued. The probability of such an effect developing is<br />greater in children and the elderly.</p><p>Confusion, emotional impoverishment, decreased vigilance, depression, increase or<br />decrease in libido.<br />Chronic use (even at therapeutic doses) may lead to the development of physical<br />dependence. Discontinuation of therapy may result in withdrawal or rebound symptoms<br />(see under Warnings and precautions / History of alcohol or medication abuse and<br />Dependence).<br />Abuse of benzodiazepines has been reported (see Warnings and<br />precautions/Dependence).<br />Musculoskeletal system<br />Muscle weakness. There have been reports of falls and fractures in benzodiazepine users.<br />The risk is increased in those taking concomitant sedatives (including alcoholic<br />beverages) and in the elderly.<br />Gastrointestinal disorders<br />Nausea, pelvic pain, diarrhea, dry mouth, constipation, hypersalivation and<br />gastrointestinal disorders.<br />Eyes<br />Diplopia, blurred vision.<br />Vascular disorders<br />Hypotension, circulatory depression.<br />Investigations<br />Irregular pulse, elevated transaminases in rare cases, elevated alkaline phosphatase.</p><p>Kidneys and urinary tract<br />Incontinence, urinary retention.<br />Skin<br />Rashes.<br />Ear<br />Vertigo.<br />Heart<br />Heart failure, including cardiac arrest.<br />Respiratory organs<br />Respiratory depression, including respiratory arrest.</p><p>Liver and biliary tract<br />Jaundice in rare cases.<br />General disorders and injection site reactions<br />Venous thrombosis, phlebitis, irritation at the injection site, local swelling and, less<br />frequently, vascular changes may occur, in particular after rapid i.v. injection.<br />Very small veins should not be used for injection; in particular intra-arterial injection and<br />extravasation should be strictly avoided.<br />Intramuscular injection may cause local irritation and erythema may occur at the injection<br />site in some cases. Tenderness is relatively common.<br />Heart and circulation/Respiration<br />Cardiorespiratory depression may occur after rectal diazepam administration.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or nurse. This includes any possible side effects<br />not listed in this leaflet. By reporting side effects you can help provide more information on the<br />safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30&deg;C and protect from light<br />Valium ampoules can be diluted with the following solutions for infusion: 0.9% sodium<br />chloride, 5% glucose and 10% glucose.<br />Opened ampoules have been shown to be chemically and physically stable for 24 hours at<br />room temperature.<br />From a microbiological point of view, the product should be used immediately unless the<br />dilute solution is prepared under controlled and validated aseptic conditions.<br />Use of PVC-containing containers and infusion sets may result in decreased<br />concentrations of diazepam (see Special dosage instructions/SPC).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance: is diazepam 10 mg/2 ml.<br />Excipients :Valium Ampoules, 10 mg/2 ml: preservative: 95 mg sodium benzoate (E211);<br />5 mg benzoic acid (E210); benzyl alcohol, propylene glycol; ethyl alcohol; 2 ml water for<br />injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Valium looks like and contents of the pack
Valium Ampoules, 10 mg/2 ml: clear injection solution containing 10 mg diazepam per 2
ml.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>F. Hoffmann-La Roche Ltd,<br />Grenzacherstrasse 124,<br />CH-4070 Basel,<br />Switzerland.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 7/ 2017
To reports any side effect(s):
• Saudi Arabia:
 The National Pharmacovigilance and Drug Safety Centre (NPC)
o Fax: +966-11-205-7662
o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.
o Toll free phone: 8002490000
o E-mail: npc.drug@sfda.gov.sa
o Website: www.sfda.gov.sa/npc

• Other GCC States:
 Please contact the relevant competent authority.

Council of Arab Health Ministers

This is a Medicament

 Medicament is a product which affects your health and its consumption contrary to
instructions is dangerous for you.
 Follow strictly the doctor’s prescription, the method of use and the instructions of the
pharmacist who sold the medicament.
 The doctor and the pharmacist are the experts in medicines, their benefits and risks.
 Do not by yourself interrupt the period of treatment prescribed for you.
 Do not repeat the same prescription without consulting your doctor.
 Keep all medicaments out of reach of children.

Council of Arab Health Ministers
Union of Arab Pharmacists
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>أمبوالت الفاليوم، 10 مج / 2 مل: محلول شفاف للحقن يحتوي على 10 مج ديازيبام لكل 2 مل.<br />الغرض الذي يستخدم فيه:<br />يستخدم الفاليوم كمخدر أساسي قبل اإلجراءات العالجية المجهدة مثل المنظار الداخلي، إزالة الصدمات الكهربائية الخارجية،<br />القسطرة القلبية، التحاليل اإلشعاعية، الجراحة البسيطة، الحد من االضطرابات والكسور، أخذ عينات انأنسجة، غيار الجرو<br />لمرضى الحروق، وغيرها لتخفيف القلق أو االرتكاسات المتوترة الحادة والمساعدة في تخفيف انألم بعد العمليات الجراحية.<br />ويستخدم الفاليوم كعالج للقلق والتوتر لدى المرضى ما قبل العمليات.<br />مؤشرات في الطب النفسي:<br />يستخدم الفاليوم كعالج للهياج المرتبط بحاالت القلق الحادة ونوبات الذعر وانأرق الحركي والهذيان االرتعاشي.<br />عالج االختالج:<br />يستخدم الفاليوم لعالج الحاالت الصرعية والتشنجية انأخرى )بما في ذلك التيتانوس(.</p><p>األمراض النسائية:<br />يستخدم الفاليوم لعالج حاالت الوالدة المتعسرة في حاالت يتم اختيارها بعناية.<br />ويستخدم الفاليوم كعالج مساعد لتخفيف التشنجات العضلية المرتبطة بالصدمات الموضعية )الجرو وااللتهابات( وعالج<br />التشنج المصاحب بالتلف الذي يصيب أوردة العمود الفقري والحبل الشوكي والتغيرات التي قد تحدث مثال نتيجة للتشنجات<br />الدماغية والشلل النصفي والتشنجات العضلية ومتالزمة الرجل المتيبس.<br />كيف يعمل الفاليوم:<br />المادة الفعالة في الفاليوم هي واحدة من فئة البنزوديازبينات التي تستخدم كمهدئات، التي تمتلك خصائص مضادات القلق<br />والمسكنات وأدوية ارتخاء العضالت ومضادات االختالج. ومن المعروف اآلن أن هذه اآلثار ترج إلى عنصر جاما<br />أمينوبوتريك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب عدم إعطاؤك الفاليوم في الحاالت التالية:<br />وجود حساسية معلومة للبنزوديازبينات أو أي من العناصر المكونة لهذا الدواء.<br />وجود فشل تنفسي حاد أو فشل كبدي حاد أو متالزمة توقف التنفس أثناء النوم أو الوهن العضلي الوبيل.<br />ال يوصى باستخدام البنزوديازبينات للعالج انأولي لالضطراب الذهاني. ويجب عدم استخدام البنزوديازبينات لعالج حاالت<br />االكتئاب أو القلق المتعلقة باالكتئاب، مثل المرضى المعرضين لالنتحار.<br />التحذيرات واالحتياطات:<br />االستخدام المتزامن للكحوليات ومثبطات الجهاز العصبي المركزي:<br />يجب تجنب االستخدام المتزامن للفاليوم مع الكحوليات أو مثبطات الجهاز العصبي المركزي. فهذا االستخدام المتزامن قد<br />يزيد من التأثير الكلينيكي للفاليوم مع النتائج المحتملة مثل التخدير الحاد أو الفشل السريري في الجهاز التنفسي و/أو الجهاز<br />القلبي الوعائي )انظر التفاعالت(.<br />التاريخ السابق من إساءة استخدام الكحوليات أو األدوية:<br />يجب استخدام الفاليوم بحرص شديد فقط مع المرضى ذوي التشخيص السابق من إساءة استخدام الكحوليات أو انأدوية أو<br />العقاقير المخدرة انأخرى. ويجب تجنب استخدام الفاليوم مع المرضى المعتمدين على العقاقير المثبطة للجهاز العصبي<br />المركزي ويشمل ذلك الكحول.<br />ويستثنى مما سبق عالج انأعراض االنسحابية الحادة. ويجب تحذير المريض من االستخدام المتزامن للكحول حيث أن هذا<br />المزيج من الممكن أن يحفز اآلثار غير المرغوبة للمادتين.<br />ويجب استخدام جرعات منخفضة للمرضى المسنين أو مرضى الوهن. ويجب توخي الحذر عند حقن الفاليوم عن طريق<br />الوريد. فقد تم تسجيل حاالت من انقطاع النفس أو توقف القلب على وجه الخصوص في المرضى المسنين والمرضى الذين<br />يعانون من أمراض شديدة الخطورة ومرضى فشل عضلة القلب أو الجهاز التنفسي.</p><p>وقد يتسبب كحول البنزيل الموجود في أمبوالت الفاليوم في حدوث أضرار مستديمة في حديثي الوالدة وال سيما المواليد<br />الخدج. ولهذا السبب، تستخدم أمبوالت الفاليوم مع هؤالء المرضى فقط في حالة عدم وجود عالج بديل.<br />ويجب توخي الحذر في حاالت الفشل القلبي التنفسي المعلومة حيث أن المهدئات مثل الفاليوم من الممكن أن تؤدي إلى تفاقم<br />فشل الجهاز التنفسي المصاب به المريض من قبل. ومن ناحية أخرى، من الممكن أن يكون التأثير المهدىء مفيدا لبعض<br />المرضى نأنه يقلل من المجهود الالزم للتنفس.<br />ويجب تجنب استخدام انأوردة الصغيرة جدا في الحقن. وعلى وجه الخصوص، ينبغي تجنب الحقن داخل الشرايين والتسريب<br />بأي ثمن، حيث أن الحقن السريع في الوريد يمكن أن يؤدي بشكل خاص إلى تخثر وريدي أو التهاب وريدي أو تهيج موضعي<br />أو تورم أو في حاالت نادرة جدا تغيرات في انأوعية الدموية.<br />ويجب اتباع اإلجراءات الوقائية المتعارف عليها عند عالج المرضى الذين يعانون من خلل في وظائف الكلى أو الكبد.<br />القلق االنتكاسي:<br />يشير مصطلح القلق االنتكاسي إلى متالزمة عابرة تتكرر فيها انأعراض التي أدت إلى العالج بالفاليوم في المقام انأول مع<br />زيادة شدتها. ويمكن أن يحدث ذلك عند التوقف عن العالج. ويمكن أن تكون هذه المتالزمة مصحوبة بارتكاسات أخرى مثل<br />التغيرات المزاجية والقلق وانأرق.<br />وبينما يزداد خطر انأعراض االنسحابية وظاهرة االنتكاس بعد التوقف المفاجئ عن العالج، فإنه يوصى بخفض الجرعة<br />تدريجيا.<br />فقدان الذاكرة:<br />من المهم انأخذ في االعتبار أن البنزوديازبينات من الممكن أن تسبب فقدان الذاكرة التقدمي. ويمكن أن يحدث هذا النوع من<br />فقدان الذاكرة أيضا مع الجرعات العالجية، ويزيد الخطر مع زيادة الجرعة. ويمكن أن يقترن تأثير فقدان الذاكرة بالسلوك<br />الغريب.<br />االرتكاسات النفسية والمتناقضة:<br />من المعروف أن البنزوديازبينات من الممكن أن تسبب ارتكاسات متناقضة مثل اإلثارة والتهيج والعدوانية وانأوهام ونوبات<br />الغضب والكوابيس والهلوسة والذهان والسلوك الغريب وغير ذلك من االضطرابات السلوكية. ويجب التوقف عن تناول هذا<br />الدواء في مثل هذه الحاالت. وتكون هذه االرتكاسات أكثر شيوعا في انأطفال والمرضى المسنين.<br />التحمل:<br />من الممكن أن تضعف االستجابة لتأثير البنزوديازبينات بعد االستخدام المتكرر للفاليوم على مدار فترة زمنية مطولة.<br />األطفال وحديثي الوالدة:<br />لم يتم دراسة تأثير وسالمة الفاليوم على انأطفال انأقل من ستة أشهر. ويجب استخدام الفاليوم في هذه الفئة العمرية فقط<br />بحرص شديد وفي غياب العالجات البديلة.<br />االعتماد:<br />من الممكن أن يترتب على استخدام البنزوديازبينات االعتماد الجسدي والنفسي. ويزداد هذا الخطر نتيجة لالستخدام المطول<br />للدواء وبجرعات كبيرة ومع المرضى المعلوم تعاطيهم للكحول و/أو المخدرات. وتحدث ظاهرة االنسحاب خاصة بعد</p><p>التوقف المفاجئ عن العالج وتقتصر في الحاالت انأكثر اعتداال على االرتعاش والهياج واضطراب النوم والقلق والصداع<br />وضعف التركيز. ومع ذلك، فقد تحدث أعراض أخرى مثل التعرق والتشنجات العضلية والبطنية واالضطرابات اإلدراكية،<br />وفي حاالت نادرة قد يحدث هذيان وتشنجات.<br />وتستمر انأعراض االنسحابية حسب مدة تأثير المادة بعد التوقف على العالج من عدة ساعات إلى أسبوعين.<br />ولتخفيف خطر االعتماد، يجب وصف البنزوديازبينات فقط بعد النظر بعناية في ضرورة إعطائها ويجب أن تعطى نأقصر<br />فترة ممكنة )عادة ال تزيد عن أربعة أسابيع عند استخدامها كمنومات على سبيل المثال(. ويجب مراجعة الحاجة إلى استمرار<br />العالج بشكل منتظم. ويوصى بالعالج لفترة أطول فقط لبعض المرضى )مثل المرضى الذين يعانون من نوبات الذعر(،<br />وفوائد البنزوديازبينات مقارنة بالمخاطر هي أقل وضوحا.<br />ولتجنب انأعراض االنسحابية، ينبغي إيقاف العالج من خالل خفض الجرعة تدريجيا لجميع المرضى. وفي حالة حدوث<br />انأعراض االنسحابية، ينبغي إجراء مراقبة طبية دقيقة ومساندة المريض.</p><p>التفاعل مع المنتجات الدوائية األخرى وأشكال التفاعل األخرى:<br />التفاعالت الحركية الدوائية:<br />يعتمد انأيض التأكسدي للديازيبام الذي يؤدي إلى تكوين إن دسميثيل ديازيبام، ثالثي هيدروكسي ديازيبام )تيمازيبام(<br />وأوكسازيبام على أيزوإنزيمات CYP2C19 و CYP3A ذات السيتوكروم P450 .ولقد أظهرت الدراسات المخبرية أن<br />أيزوفورم CYP3A مسؤول بشكل رئيسي عن الهيدروكسيل بينما كل من CYP3A و CYP2C19 مسؤوالن عن نزع<br />الميثيل إن. ولقد تأكدت هذه النتائج المخبرية من خالل الدراسات التي أجريت على المتطوعين. وقد تؤثر الركائز المعدلة<br />لإلنزيمات CYP3A و/أو CYP2C19 على الحركية الدوائية للديازيبام. أما مثبطات CTP3A و CYP2C19 مثل<br />سيميتيدين، كيتوكونازول، فلوفوكسامين، توبيراميت، فلوكسيتين، أوميبرازول فقد تسبب تهدئة أقوى لفترة أطول. وباإلضافة<br />إلى ذلك، فقد تم تسجيل حاالت يتسبب فيها ديازيبام في تعديل المحو انأيضي للفينيتوين.<br />التفاعالت الدوائية:<br />قد يتفاقم تأثير الفاليوم على التهدئة والتنفس والدورة الدموية عند تناوله متزامنا مع مثبطات الجهاز العصبي المركزي مثل<br />مضادات الذهان ومضادات القلق والمهدئات ومضادات االكتئاب والمنومات ومضادات التشنجات والمسكنات المخدرة وأدوية<br />التخدير ومضادات الهيستامين المهدئة والكحول.<br />لذلك يجب على المرضى الذين يتناولون الفاليوم تجنب تعاطي الكحوليات )انظر التحذيرات واالحتياطات(.<br />وللمزيد من الملحوظات عن مثبطات الجهاز العصبي المركزي، ومنها الكحول، انظر الجزء الخاص بالجرعة الزائدة.<br />وقد يثبط الثيوفيلين مفعول الديازيبام.<br />ومن ناحية أخرى، ال توجد تفاعالت مع أدوية السكر ومضادات التخثر ومدرات البول انأكثر استعماال.<br />ويعتبر الريفامبيسين محفز قوي لإلنزيمات الكبدية. وقد يسرع من عملية التمثيل الغذائي للديازيبام في الكبد.<br />وعند إعطاء الفاليوم مع انأفيونات التي تسبب هبوط تنفسي، يجب انأخذ في االعتبار زيادة احتمالية تفاقم هذا الهبوط وحدوث<br />فشل تنفسي.</p><p>الحمل:<br />يجب عدم استخدام الفاليوم أثناء الحمل إال في الضرورة القصوى نظرا نأن الديازيبام ونواتج انأيض الخاصة به تمر عبر<br />المشيمة. وقد يؤدي استخدام البنزوديازبينات لفترات طويلة أثناء الحمل إلى حدوث انخفاض في ضغط الدم وهبوط تنفسي<br />وانخفاض في درجة الحرارة عند المواليد. وتم تسجيل انأعراض االنسحابية أحيانا مع هذه الفئة من العقاقير في المواليد.<br />ويجب توخي الحذر خصوصا عند استخدام الفاليوم أثناء الوالدة حيث أن الجرعات العالية منه قد تسبب عدم انتظام ضربات<br />القلب للجنين وانخفاض ضغطه وحرارته وضعف قدرته على الرضاعة وهبوط تنفسي حاد نوعا ما للمولود )متالزمة الرضع<br />المرنة(. ويجب انأخذ في االعتبار أن نظام اإلنزيمات المسؤول عن تكسير الديازيبام ال يكون كامل النمو عند المواليد<br />)وبانأخص انأطفال الخدج(.<br />اإلرضاع:<br />يتم إفراز الديازيبام ومواد انأيض الناتجة عنه في حليب الثدي. ويجب التوقف عن الرضاعة الطبيعية في الحاالت التي<br />تستدعي استخدام الفاليوم أثناء الرضاعة.<br />التأثيرات على القدرة على قيادة السيارات واستخدام اآلالت:<br />الفاليوم له تأثير واضح على القدرة على قيادة السيارات واستخدام اآلالت. ويجب تحذير المرضى الذين يتناولون الفاليوم من<br />القيام بانأنشطة التي تتطلب اليقظة الذهنية الكاملة، وتشمل هذه انأنشطة تشغيل اآلالت الخطرة وقيادة السيارات. كما ينبغي<br />تحذير المرضى الذين يتناولون الفاليوم من التعاطي المتزامن للمشروبات الكحولية نأن هذا المزيج يمكن أن يفاقم اآلثار غير<br />المرغوبة لكل من المادتين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>الحقن: في بعض الحاالت الحرجة إذا لزم انأمر أو عندما تكون االستجابة عن طريق الفم غير كافية، يجب إعطاء جرعات<br />أعلى عن طريق الحقن.<br />جرعات الحقن الموصي بها بشكل عام للبالغين والمراهقين تتراو بين 2 &ndash; 20 مج حقن في العضل أو الوريد اعتمادا على<br />وزن الجسم وشدة وداللة انأعراض التي يتم عالجها. ويمكن إعطاء جرعات أعلى في بعض الحاالت مثل التيتانوس.<br />ويجب إعطاء الحقنة الوريدية للفاليوم ببطء )حوالي 5.0 &ndash; 1 مل في الدقيقة( نظرا نأن سرعة الحقن قد تسبب انقطاع النفس.<br />ويجب أن تكون أدوات اإلنعاش جاهزة لالستخدام دائما وفي متناول اليد.<br />تعليمات الجرعة الخاصة:<br />انأمبوالت:<br />هناك أدلة على أن الديازيبام يمكن امتصاصه داخل أكياس الضخ البالستيكية وأجهزة الضخ التي تحتوي على كلوريد البولي<br />فينيل مما يؤدي إلى انخفاض في تركيز الديازيبام بنسبة 50 %أو أكثر، وخاصة عندما يتم تخزين انأكياس المجهزة لمدة 24<br />ساعة أو أكثر في الظروف المحيطة الدافئة، أو عند استخدام انأنابيب الطويلة أو معدالت الضخ البطيئة. ويجب تجنب<br />انأكياس وأجهزة الضخ التي تحتوي على كلوريد البولي فينيل عند ضخ الديازيبام، ويجب توخي الحذر عند التبديل بين<br />انأكياس وأجهزة الضخ المحتوية وغير المحتوية على كلوريد البولي فينيل.<br />حديثي الوالدة:<br />يجب استخدام انأمبوالت مع هذه الفئة فقط في غياب البدائل العالجية انأخرى )انظر التحذيرات واالحتياطات(.</p><p>التخدير:<br />قبل التخدير: 10 &ndash; 20 مج )انأطفال: 1.0 &ndash; 2.0 مج لكل كيلوجرام من وزن الجسم( حقن في العضل قبل التخدير بساعة<br />واحدة.<br />التخدير: 2.0 &ndash; 5.0 مج لكل كيلوجرام من وزن الجسم حقن في الوريد.<br />للتنويم قبل اإلجراءات والفحوصات المجهدة: 10 &ndash; 30 مج )انأطفال: 1.0 &ndash; 2.0 مج لكل كيلوجرام من وزن الجسم(<br />حقن في الوريد.<br />أفضل طريقة لضبط الجرعة لكل مريض هي إعطاء حقنة أولية قدرها 5 مج = 1 مل )أو 1.0 مج لكل كيلوجرام من وزن<br />الجسم( متبوعة بحقن جرعات متكررة قدرها 5.2 مج )أو 05.0 مج لكل كيلوجرام من وزن الجسم( كل 30 ثانية حتى<br />إغالق الجفون.<br />انأمراض النسائية:<br />التشنجات: للنوبات الحالية أو الوشيكة: يتم حقن 10 &ndash; 20 مج في الوريد، ثم إعطاء جرعات إضافية حسب االقتضاء عن<br />طريق الحقن الوريدية أو المحلول الوريدي )بحد أقصى 100 مج خالل 24 ساعة(.<br />تسهيل عملية الوالدة: 10 &ndash; 20 مج حقن في العضل )ويمكن إعطاء حقن وريدية في حاالت التوتر الحاد( عند اتساع عنق<br />الرحم مسافة 2 &ndash; 5 سم. ويتم حقن 10 &ndash; 20 مج في الوريد لتسهيل عمليات الوالدة وخياطة جر الفرج.<br />التيتانوس:<br />يتم حقن 1.0 &ndash; 3.0 مج لكل كيلوجرام من وزن الجسم في الوريد كل 1 &ndash; 4 ساعات أو عن طريق محلول )3 &ndash; 4 مج لكل<br />كيلوجرام من وزن الجسم خالل 24 ساعة(، ويمكن أيضا إعطاء نفس الجرعة متزامنة عن طريق أنبوب التغذية.<br />حاالت الصرع:<br />يتم حقن 15.0 &ndash; 25.0 مج لكل كيلوجرام من وزن الجسم في الوريد، ويمكن تكرار الجرعة عند اللزوم بعد 10 &ndash; 15<br />دقيقة، ويمكن إعطاء محلول )أقصى جرعة 3 مج لكل كيلوجرام من وزن الجسم خالل 24 ساعة(.<br />الهياج:<br />في حاالت القلق الحادة وانأرق الحركي والهذيان االرتعاشي، يتم إعطاء حقنة أولية قدرها 1.0 &ndash; 2.0 مج لكل كيلوجرام من<br />وزن الجسم في الوريد، ويمكن تكرارها كل 8 ساعات حتى زوال انأعراض الحادة، وبعدها يستمر العالج عن طريق الفم.<br />جميع أشكال الجرعات:<br />يجب إعطاء جرعات أقل للمرضى كبار السن ومرضى الكبد. ويجب فحص هؤالء المرضى بانتظام في بداية العالج بحيث<br />يمكن تقليل الجرعة إذا لزم انأمر و/أو إطالة مدة الجرعة لتجنب الجرعة الزائدة.<br />ويجب النظر في تقليل الجرعة بعد حوالي أسبوع من العالج.</p><p>مدة العالج:<br />يجب أن تكون مدة العالج قصيرة قدر اإلمكان. ويجب إعادة تقييم المريض على فترات منتظمة وتحديد الحاجة إلى استمرار<br />العالج، وخاصة إذا لم يعد المريض يعاني من أي أعراض. ويجب أال تتجاوز مدة العالج، شاملة فترة تقليص الجرعات،<br />شهرين &ndash; ثالثة أشهر. وال ينبغي التفكير في العالج طويل انأمد إال بعد إعادة تقييم الحالة. وفي بداية العالج، قد يكون من<br />المفيد إبالغ المريض أن مدة العالج ستكون محدودة وأن يشر له بالتفصيل كيف سيتم سحب الجرعة.<br />ومن المهم أيضا إبالغ المريض بإمكانية حدوث ظاهرة االنتكاس حتى ال يقلق عند حدوثها. وهناك أدلة على أنه مع<br />البنزوديازبينات قصيرة المفعول، يمكن أن تحدث ظاهرة االنسحاب حتى خالل الفترة بين الجرعات، خاصة مع الجرعات<br />العالية. وعند استخدام البنزوديازبينات طويلة المفعول مثل الديازيبام، فمن الضروري تحذير المريض من التحول إلى<br />البنزوديازبين قصير المفعول، نأن ذلك يمكن أن يؤدي إلى ظاهرة االنسحاب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>تتمثل اآلثار غير المرغوب فيها انأكثر شيوعا للفاليوم في التعب والنعاس والوهن العضلي، وهي عادة أعراض ذات صلة<br />بالجرعة. وتحدث هذه االرتكاسات بصفة أساسية عند بدء العالج وتتالشى بشكل عام مع االستخدام المطول.<br />الدم والجهاز الليمفاوي:<br />ارتفاع معدالت الفوسفات القلوي في الدم مع الحقن الوريدي.<br />-<br />االضطرابات النفسية:<br />تظهر التجارب حدوث بعض االرتكاسات مثل انأرق والهياج والعدوانية وانأوهام والغضب والكوابيس والهالوس والذهان<br />والسلوك الغريب وغيرها من اآلثار السلوكية غير المرغوب بها مع استخدام البنزوديازبينات. ويجب إيقاف الدواء في مثل<br />هذه الحاالت. وتزداد احتمالية حدوث مثل هذه اآلثار الجانبية مع انأطفال والمسنين.<br />وقد يحدث االرتباك ونقص العاطفة وانخفاض اليقظة واالكتئاب وزيادة أو انخفاض الرغبة الجنسية.<br />وقد يؤدي االستخدام المزمن للفاليوم )حتى في الجرعات العالجية( إلى تطوير االعتماد الجسدي. وقد يؤدي إيقاف العالج إلى<br />ظهور أعراض االنسحاب أو االرتكاس )انظر التحذيرات واالحتياطات / التعاطي السابق للكحول أو العقاقير واالعتماد(.<br />ولقد تم تسجيل إساءة استخدام البنزوديازبينات )انظر التحذيرات واالحتياطات / االعتماد(.<br />الجهاز العضلي الهيكلي:<br />قد يحدث الضعف العضلي للمريض المعتمد على الفاليوم. ولقد تم تسجيل حاالت من السقوط والكسور لدى مستخدمي<br />البنزوديازبينات. ويزداد الخطر بالنسبة للمرضى المعتمدين على المهدئات والمثبطات المتزامنة )ويشمل ذلك المشروبات<br />الكحولية( وفي كبار السن.<br />اضطرابات الجهاز الهضمي:<br />ويشمل ذلك الغثيان وألم البطن واإلسهال وجفاف الفم واإلمساك وزيادة اللعاب واالضطرابات الهضمية.</p><p>العينين:<br />الحول وازدواج الرؤية.<br />االضطرابات الوعائية:<br />انخفاض الضغط وهبوط الدورة الدموية.<br />الفحوصات:<br />عدم انتظام النبض، زيادة اإلنزيمات الناقلة لألمين في حاالت نادرة، زيادة معدل الفوسفات القلوي.<br />الكلى وقناة مجرى البول:<br />سلس البول، االحتباس البولي.<br />الجلد:<br />الطفح الجلدي.<br />األذن:<br />الدوار.<br />القلب:<br />هبوط القلب، ويشمل ذلك السكتة القلبية.<br />الجهاز التنفسي:<br />هبوط التنفس، ويشمل ذلك توقف النفس.<br />الكبد والقنوات الصفراوية:<br />الصفراء في حاالت نادرة.<br />االضطرابات العامة واالرتكاسات في مكان الحقن:<br />قد يحدث التجلط الوريدي والتهاب الوريد والتهيج في مكان الحقن والتورم الموضعي، وفي حاالت أقل شيوعا قد يحدث<br />تغيرات في انأوعية الدموية وخصوصا بعد الحقن الوريدي السريع.<br />ال ينبغي استخدام انأوردة الصغيرة جدا للحقن، وال سيما الحقن داخل الشرايين، ويجب تجنب التسريب تماما.<br />وقد يسبب الحقن العضلي تهيجا واحمرار محتمال في مكان الحقن في بعض الحاالت. وقد يحدث ألم في حاالت شائعة نسبيا.<br />القلب والدورة الدموية / التنفس:<br />قد يحدث هبوط قلبي تنفسي بعد إعطاء الديازيبام عن طريق المستقيم.</p><p>تسجيل األعراض الجانبية:<br />يجب عليك استشارة الطبيب أو التمريض في حالة حدوث أي من اآلثار الجانبية المذكورة أعاله أو تفاقمها أو مالحظة أي آثار<br />جانبية غير مدرجة في هذه النشرة. فمن خالل تسجيل اآلثار الجانبية يمكنك المساعدة في توفير المزيد من المعلومات حول<br />سالمة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يخزن في درجة حرارة أقل من 30 درجة مئوية ويحفظ بعيدا عن الضوء.<br />يمكن تخفيف أمبوالت الفاليوم بالمحاليل التالية للحقن: 9.0 %كلوريد الصوديوم، 5 %جلوكوز، 10 %جلوكوز.<br />أظهرت انأمبوالت المفتوحة ثباتها الكيميائي والفيزيائي لمدة 24 ساعة في درجة حرارة الغرفة.<br />من المنظور الميكروبيولوجي، يمكن استخدام المنتج على الفور ما لم يجهز محلول التخفيف في ظروف مراقبة ومعقمة.<br />قد يترتب على استخدام الحاويات وأجهزة الضخ المحتوية على كلوريد البولي فينيل انخفاض تركيزات الديازيبام )انظر<br />تعليمات الجرعة الخاصة(.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هيا الديازيبام 10 مج / 2 مل.<br />المواد غير الفعالة: أمبوالت الفاليوم، 10 مج / 2 مل. حافظة: 95 مج بنزوات الصوديوم )E211 ،)5 مج حمض<br />البنزويك )E210 ،)كحول البنزيل، جليكول البروبيلين، كحول إيثيلي، 2 مل ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>شكل عقار الفاليوم ومحتويات العبوة:<br />أمبوالت فاليوم، 10 مج / 2 مل: محلول شفاف للحقن يحتوي على 10 مج ديازيبام لكل 2 مل.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>إف. هوفمان &ndash; ال روش ليميتد،<br />124 شارع جرينزاشر، 4070-CH بازل، سويسرا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر مراجعة لهذه النشرة بتاريخ 7/2017.
لتسجيل أي آثار جانبية:
المملكة العربية السعودية:
- المركز الوطني للتيقظ والسالمة الدوائية )إن بي سي(
+966-11-205-7662 :فاكس
2340 – 2334 – 2354 – 2353 – 2356 – 2317 :داخلي+ 966-11-2038222 :هاتف
الهاتف المجاني: 8002490000
npc.drug@sfda.gov.sa :اإللكتروني البريد
www.sfda.gov.sa/npc :اإلنترنت على الموقع

المملكة العربية السعودية 7/2017
أمبوالت فاليوم، إصدار رقم 9

نشرة معلومات المريض
فاليوم 10 مج / 2 مل أمبوالت

10

دول الخليج األخرى:
- يرجى االتصال بالجهة المختصة.
مجلس وزراء الصحة العرب:

هذا الدواء:

- هذا الدواء منتج يؤثر على صحتك واستهالكه بطريقة مخالفة للتعليمات يعرض حياتك للخطر.
- اتبع إرشادات الطبيب وطريقة االستخدام وتعليمات الصيدلي الذي باع لك هذا الدواء.
- الطبيب والصيدلي هم خبراء في انأدوية وفوائدها ومخاطرها.
- ال تتوقف من تلقاء نفسك عن العالج الموصوف لك.
- ال تكرر نفس الوصفة الطبية من تلقاء نفسك دون استشارة الطبيب.
- تحفظ جميع انأدوية بعيدا عن متناول انأطفال.
مجلس وزراء الصحة العرب
اتحاد الصيادلة العرب
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Valium Ampoules, 10 mg/2 ml
Black Box Warning:
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS
- Concomitant use of benzodiazepines and opioids may result in
profound sedation, respiratory depression, coma, and death.
- Reserve concomitant prescribing of these drugs for use in
patients for whom alternative treatment options are inadequate.
- Limit dosages and durations to the minimum required.
- Follow patients for signs and symptoms of respiratory
depression and sedation.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Active ingredient: diazepam.
- Excipients:
Valium Ampoules, 10 mg/2 ml: preservative: 95 mg sodium benzoate (E211); 5 mg
benzoic acid (E210); benzyl alcohol, propylene glycol; ethyl alcohol; 2 ml water for
injections.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for Injection, Clear injection solution containing 10 mg diazepam per 2 ml.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The injectable forms of Valium are indicated for:<br />Conscious sedation: diagnostic and therapeutic interventions such as cardioversion,<br />cardiac catheterization, endoscopy, radiological procedures, minor surgical interventions,<br />reduction of dislocations and fractures, biopsies, dressing of burns, etc. in order to relieve<br />apprehension, anxiety, acute stress and to diminish recollections of such procedures.<br />Premedication and induction of anaesthesia: allaying anxiety and tension prior to<br />surgical procedures.</p><p>Excitation: In psychiatry, Valium is used in the treatment of excitation states associated<br />with psychiatric disorders including acute anxiety and panic, as well as in motor unrest<br />and delirium tremens.<br />Anticonvulsant effect: the treatment of status epilepticus and other convulsive states<br />Gynaecology and obstetrics: second line treatment of eclampsia (if magnesium sulphate<br />is unavailable or if seizures continue despite administration of magnesium sulphate).<br />Muscle relaxation: an adjunct for the relief of reflex muscle spasm (including tetanus)<br />due to local trauma. It is indicated for combating spasticity arising from damage to spinal<br />and supraspinal interneurons such as cerebral palsy and paraplegia, as well as in athetosis<br />and stiff-man syndrome.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Standard dosage<br />For optimal effect, the dosage should be carefully individualized. The usual daily doses<br />given below will meet the needs of most patients, though there will be cases requiring<br />higher doses.<br />In adults and juveniles, a parenteral dose 2-20 mg i.m. or i.v. is generally recommended,<br />depending on bodyweight, indication and severity of symptoms. In some indications (e.g.<br />tetanus) higher doses may occasionally be required. Elderly patients and those with<br />impaired hepatic function should be given a reduced dose (see section 4.2 Special Dosage<br />Instructions). These patients should be checked regularly at the start of treatment in order<br />to minimize the dosage and/or the frequency of administration to prevent overdose due to<br />accumulation.<br />I.V. injection of Valium should always be slow (approximately 0.5-1 ml per minute), as<br />excessively rapid administration can lead to apnoea; resuscitation apparatus must be kept<br />ready at all times.<br />Anaesthesiology<br />Premedication and induction of anaesthesia: For premedication: 10-20 mg i.m.; children<br />0.1-0.2 mg/kg bodyweight, 1 hour before induction of anaesthesia. For induction of<br />anaesthesia: 0.2-0.5 mg/kg bodyweight i.v.<br />Conscious sedation before stressful therapeutic interventions: 10-20 mg i.v. and in<br />particularly heavy patients 30 mg i.v.; children 0.1-0.2 mg/kg bodyweight. Adapting the<br />dose to the patient&rsquo;s individual needs consists of an initial injection of 5 mg (1 ml), or 0.1<br />mg/kg bodyweight in children, followed every 30 seconds by increments of 50% of the<br />initial dose.Gynaecology and obstetrics<br />Eclampsia: For actual or threatened convulsions where magnesium sulphate is<br />unavailable: 10-20 mg i.v.; additional doses, as required, either i.v. or by continuous<br />infusion (up to 100 mg in 24 hours). If seizures continue despite the administration of<br />magnesium sulphate, Valium can be administered at a dose of 5-10 mg i.v .<br />Tetanus<br />0.1-0.3 mg/kg bodyweight should be given i.v. in intervals at 1-4 hours. Alternatively by<br />continuous infusion or gastric tube (3-4 mg/kg bodyweight in 24 hours).<br />Status epilepticus<br />Anticonvulsant effect in status epilepticus: 0.15-0.25 mg/kg bodyweight should be given<br />i.v., repeated as necessary after 10-15 minutes or by continuous infusion. Maximum dose:<br />3 mg/kg bodyweight in 24 hours.<br />Excitation states<br />Excitation in acute anxiety states, motor unrest or delirium tremens: Initially 0.1-0.2<br />mg/kg bodyweight i.v., repeated at 8-hourly intervals until acute symptoms subside, then<br />continue with oral treatment.<br />Special dosage instructions<br />There is evidence that diazepam can be adsorbed within plastic infusion bags and<br />infusion sets especially those containing PVC and leading to a reduction in diazepam<br />concentration by 50% or more, especially where prepared bags are stored for 24 hours or<br />more, in warm ambient conditions, or where long tubing sets or slow rates of infusion are<br />used. If possible PVC-containing bags and infusion sets should be avoided when infusing<br />diazepam. When infusing diazepam caution should be exercised when switching between<br />PVC and non-PVC-containing bags and infusion sets<br />Geriatric use<br />Dosage for elderly patients: The lowest possible dose should be used in the elderly (see<br />5.2 Use in Special Populations; Geriatric Use). These patients should be checked<br />regularly at the start of treatment in order to minimize the dosage and/or the frequency of<br />administration to prevent overdose due to accumulation (see 5.2 Pharmacokinetics in<br />Special Populations).<br />Pediatric use<br />Children&rsquo;s dosage: 0.1-0.3 mg/kg bodyweight daily. Benzodiazepines should not be given<br />to children without careful assessment of the indication; the duration of treatment must be<br />kept to a minimum.Hepatic Impairment<br />Patients with severe hepatic impairment should not be treated with Valium tablets (see<br />section 4.3 Contraindications). In patients with mild or moderate hepatic impairment, the<br />lowest dose possible should be given.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Valium is contraindicated in patients with a known history of hypersensitivity to
benzodiazepines.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant use of alcohol / CNS depressants<br />The concomitant use of Valium with alcohol or/and CNS depressants should be avoided.<br />Such concomitant use has the potential to increase the clinical effects of Valium possibly<br />including severe sedation that could result in coma or death, clinically relevant respiratory<br />and/or cardio-vascular depression (see 4.5 Interactions with other Medicinal Products and<br />other Forms of Interactions and 4.9 Overdose).</p><p>Medical history of alcohol or drug abuse<br />Valium should be used with extreme caution in patients with a history of alcohol or drug<br />abuse.<br />Valium should be avoided in patients with dependence on CNS depressants including<br />alcohol.<br />An exception to the latter is the management of acute withdrawal reactions.</p><p>Hepatic impairment<br />Benzodiazepines may have a contributory role in precipitating episodes of hepatic<br />encephalopathy in severe hepatic impairment. Special caution should be exercised when<br />administering Valium to patients with mild to moderate hepatic impairment (see 4.3<br />Contraindications).<br />Psychiatric and &#39;paradoxical&#39; reactions<br />Paradoxical reactions such as restlessness, agitation, irritability, aggressiveness, anxiety,<br />delusion, anger, nightmares, hallucinations, psychoses, inappropriate behaviour and other<br />adverse behavioural effects are known to occur when using benzodiazepines. Should this</p><p>August 2015 Saudi Arabia &ndash; Summary of Product Characteristic (SPC)<br />Ref CDS 9.0 7/2017 Valium ampoules</p><p>July 2017 SPC<br />occur, the use of the drug should be discontinued. They are more likely to occur in<br />children and in the elderly.</p><p>Amnesia<br />It should be borne in mind that benzodiazepines may induce anterograde amnesia.<br />Anterograde amnesia may occur using therapeutic dosages, the risk increasing at higher<br />dosages. Amnestic effects may be associated with inappropriate behavior.<br />Tolerance<br />Some loss of response to the effects of benzodiazepines may develop after repeated use of<br />Valium for a prolonged time.<br />Pediatric use<br />Since the safety and effectiveness in paediatric patients below the age of 6 months have<br />not been established, Valium should be used in this age group with extreme caution and<br />only when other therapeutic alternatives are not available.<br />Geriatric use<br />Lower doses should be used for elderly and debilitated patients.<br />Respiratory Insufficiency<br />A lower dose is recommended for patients with chronic respiratory insufficiency, due to<br />the risk of respiratory depression.<br />As with any substance with CNS depressant and/or muscle-relaxant properties, particular<br />care should be taken when administering Valium to a patient with myasthenia gravis,<br />owing to pre-existing muscle weakness.<br />Care must be used in administering injectable Valium, particularly by the i.v. route, to the<br />elderly, to very ill patients and to those with limited pulmonary reserve because of the<br />possibility that apnoea and/or cardiac arrest may occur.<br />The benzyl alcohol contained in Valium ampoules may lead to irreversible damage in the<br />newborn, especially in the premature. Therefore, for these patients the ampoules should<br />only be used if no therapeutic alternative is available.<br />Very small veins should not be selected for injection. In particular, intra-arterial injection<br />or extravasation must be strictly avoided because venous thrombosis, phlebitis, local<br />irritation, swelling or - less frequently - vascular changes may occur, particularly after<br />rapid i.v. injection.<br />Valium ampoules should be used with caution in patients with sleep apnoea due to<br />possible additive effects on respiratory depression.</p><p>August 2015 Saudi Arabia &ndash; Summary of Product Characteristic (SPC)<br />Ref CDS 9.0 7/2017 Valium ampoules</p><p>July 2017 SPC<br />Dependence<br />Use of benzodiazepines and benzodiazepine-like agents may lead to the development of<br />physical and psychological dependence (see 4.8 Undesirable Effects). The risk of<br />dependence increases with dose and duration of treatment; it is also greater in<br />patients with a medical history of alcohol and/or drug abuse. Abuse has been<br />reported in poly-drug abusers . Valium should be used with extreme caution in<br />patients with a history of alcohol or drug abuse.<br />Withdrawal<br />Once physical dependence has developed, abrupt termination of treatment will be<br />accompanied by withdrawal symptoms. These may consist of headache, diarrhea,<br />muscle pain, extreme anxiety, tension, restlessness, confusion and irritability. In<br />severe cases, the following symptoms may occur: derealization, depersonalization,<br />hyperacusis, numbness and tingling of the extremities, hypersensitivity to light,<br />noise and physical contact, hallucinations or convulsions.<br />When benzodiazepines are used, withdrawal symptoms may develop when switching to a<br />benzodiazepine with a considerably shorter elimination half-life.<br />Rebound anxiety<br />A transient syndrome whereby the symptoms that led to treatment with Valium recurs in<br />an enhanced form. This may occur on withdrawal of treatment. It may be<br />accompanied by other reactions including mood changes, anxiety, sleep<br />disturbances, and restlessness.<br />Since the risk of withdrawal phenomena and rebound phenomena is greater after abrupt<br />discontinuation of treatment, it is recommended that the dosage be decreased<br />gradually.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The metabolism of diazepam and its main metabolite, DMDZ depends on the cytochrome<br />P450 isozymes CYP3A4 and CYP2C19. Modulators of these enzymes may lead to<br />changes in diazepam disposition and effects. Strong interactions are seen with compounds<br />which affect both of diazepam&rsquo;s oxidative metabolic pathways simultaneously; moderate<br />effects only occur even with strong inhibitors if they affect only one of diazepam&rsquo;s<br />metabolic pathways . Inhibitors of CYP3A4 and CYP2C19 decrease metabolic rate and<br />may led to higher than normal concentrations of diazepam and the desmethyl metabolite<br />and consequently to increased/ prolonged sedation and anxiolytic effects. Such changes<br />may exacerbate diazepam&rsquo;s effects in patients with increased sensitivity, e.g. due to their<br />age, reduced liver function or treatment with other drugs that impair oxidation. Inducers<br />of CYP3A4 and CYP2C19 may lead to lower than expected concentrations and hence to<br />a lack of desired efficacy.</p><p>Effect of other drugs on the pharmacokinetics of diazepam:<br />Enzyme inhibitors<br />Grapefruit juice contains strong inhibitors of CYP3A4. Diazepam exposure was strongly<br />increased (AUC 3.2-fold; Cmax 1.5-fold) and time to reach maximum concentration was<br />delayed when diazepam was given with grapefruit juice instead of water [144].<br />Antimycotic azole derivatives inhibit CYP3A4 and CYP2C19 pathways and lead to<br />increased exposure to diazepam (diazepam AUC ratio fluconazole 2.5; voriconazole 2.2)<br />and prolonged elimination half-life of diazepam (with fluconazole from 31 h to 73 h; with<br />voriconazole from 31h to 61 h). The influence of the antimycotics on diazepam levels<br />was only seen at 4 hours after administration and beyond. Itraconazole has a more<br />moderate effect with no clinically significant interaction with diazepam as determined by<br />psychomotor performance tests.<br />The serotonin reuptake inhibitor fluvoxamine is also an inhibitor of both of diazepam&rsquo;s<br />degradation pathways and increased not only exposure to diazepam by 180% and<br />prolonged its elimination half-life from 51 h to 118 h, but also increased exposure and<br />time to reach steady state of the desmethyl metabolite. Fluoxetine showed a more<br />moderate effect on diazepam AUC (approximately 50% increase) and did not affect</p><p>psychomotor response because combined concentrations of diazepam and desmethyl-<br />diazepam were similar with and without fluoxetine .</p><p>Combined hormonal contraceptives appear to reduce the clearance (by 67%) and prolong<br />elimination half-life (by 47%) of diazepam . Diazepam-induced psychomotor impairment<br />in women on contraceptives may be higher during the 7-day menstrual pause when off the<br />hormone preparation than when taking the contraceptive (159). There is some limited<br />evidence that benzodiazepines can increase the incidence of break-through bleeding in<br />women with hormonal contraceptives. A drug interaction causing pregnancy was not<br />observed.<br />The proton pump inhibitor omeprazole, a CYP2C19 and CYP3A4 inhibitor, administered<br />at a dose of 20 mg o.d. increased the diazepam AUC by 40% and the half-life by 36%, at<br />a dose of 40 mg o.d. omeprazole increased the diazepam AUC by 122% and the half-life<br />by 130%. The elimination of desmethyl-diazepam was reduced as well. The effect of<br />omeprazole was only seen in extensive but not slow metabolizers of CYP2C19.<br />Esomeprazole (but not lansoprazole or pantoprazole) has the potential to inhibit the<br />metabolism of diazepam to a similar degree as omeprazole.<br />The histamine H2-receptor antagonist cimetidine, an inhibitor of multiple CYP isozymes,</p><p>including CYP3A4 and CYP2C19, reduces the clearance of diazepam and of desmethyl-<br />diazepam by 40 to 50%. The effect is no different after one day or after chronic treatment</p><p>with cimetidine and results in higher exposure to and a prolonged elimination half-life of<br />diazepam and its main metabolite after single dosing and to higher steady-state</p><p>concentrations after multiple dosing of diazepam. Enhanced sedation was seen with co-<br />administration of cimetidine. No such pharmacokinetic interaction was seen with the H2-</p><p>antagonists ranitidine and famotidine.Disulfiram inhibits the metabolism of diazepam (median decrease in clearance 41%,<br />increase in half-life 37%) and probably the further metabolism of diazepam&rsquo;s active<br />metabolites. Enhanced sedative effects may result.<br />Antituberculosis therapy may change the disposition of diazepam. In presence of<br />isoniazid diazepam mean exposure (AUC) and half-life were increased (on average 33-<br />35%) with the largest changes seen in subjects with slow-acetylator phenotype.<br />The calcium channel blocker diltiazem, a substrate for the same CYP isozymes as<br />diazepam and an inhibitor of CYP3A4, increased AUC (by approximately25%) and<br />prolonged half-life (by 43% in extensive CYP2C19 metabolizers) of diazepam with little<br />differences between subjects with different CYP2C19 phenotypes. In the presence of<br />diltiazem exposure to desmethyl-diazepam also tended to increase .<br />The primary metabolite of idelalisib is a strong CYP3A4 inhibitor and increases the<br />serum concentrations of diazepam so that dose reduction may have to be considered.<br />The psychostimulants modafinil and armodafinil induce CYP3A4 and inhibit CYP2C19;<br />they may prolong the elimination of diazepam and cause excessive sedation .<br />Enzyme inducers<br />Rifampicin very potently induces CYP3A4 and has also a significant accelerating effect<br />on the CYP2C19 pathway. When dosed at 600 mg daily for 7 days, diazepam clearance<br />was increased 4.3-fold and AUC decreased by -77%. A significant reduction in exposure<br />to all diazepam metabolites was also observed. Doubling the daily rifampicin dose did not<br />further increase its effect.<br />Carbamazepine is a known inducer of CYP3A4 and accelerated elimination (increased<br />clearance, reduced half-life) of diazepam 3-fold while increasing concentrations of<br />desmethyl-diazepam.<br />Food and Antacids<br />Food and antacids may lower the rate but will not lower the extent of diazepam<br />absorption from the tablet; this may lead to attenuated effects after a single dose but not<br />influence steady-state concentrations during multiple-dose therapy.<br />Prokinetic drugs increase the rate of diazepam absorption.<br />Intravenous but not oral metoclopramide increases the rate of absorption of diazepam and<br />increases the maximum concentration achieved after oral dosing.<br />Narcotics (morphine, pethidine) decrease the absorption rate and lower peak<br />concentrations of orally administered diazepam.<br />Effect of diazepam on the pharmacokinetics of other drugs<br />Diazepam has not been found to induce or inhibit metabolizing enzymes. Nevertheless<br />some interactions with other drugs occur where diazepam is the precipitant.Phenytoin therapy was associated with higher concentrations and increased phenytoin<br />intoxication when combined with diazepam. However, some authors have found no<br />interaction or even lowered plasma concentrations of phenytoin when co-administered<br />with diazepam.<br />- Pharmacodynamic interactions (DDI)Alcohol should be avoided in patients receiving Valium (see 4.4 General (Warnings and<br />Precautions)).<br />See section 4.9 Overdose for warning of other central nervous system depressants<br />including alcohol.<br />Enhanced side effects such as sedation and cardio-respiratory depression may also occur<br />when Valium is co-administered with any centrally acting depressants including<br />alcohol.<br />There are several reports of severe hypotension, respiratory depression or loss of<br />consciousness in patients under combined treatment with clozapine and<br />benzodiazepines, including diazepam .<br />Additive CNS depressant effects can be expected when combining phenothiazines and<br />benzodiazepines; sedation, respiratory depression and airway obstruction has been<br />reported with the combined use of levopromazine and diazepam.<br />Additive effects of olanzapine and diazepam on sedation and hypotension occur in the<br />absence of a pharmacokinetic interaction. Concomitant parenteral use is not<br />recommended.<br />Diazepam boosts the subjective opioid effects of methadone. It increases methadone<br />effects on pupil diameter and sedation and also causes significantly greater<br />deterioration in reaction time when compared to methadone alone . No<br />pharmacokinetic interaction occurs between the two drugs .<br />Reversible loss of control of Parkinson&rsquo;s disease has been seen in some patients treated<br />with combined levodopa and diazepam. This might be caused by decreased striatal<br />dopamine levels.<br />The xanthines theophylline and caffeine oppose the sedative and possibly anxiolytic<br />effects of diazepam partially through blocking of adenosine receptors.<br />Diazepam pretreatment changes the pharmacodynamics and pharmacokinetics of the<br />anaesthetic ketamine. Ketamine N-demethylation was inhibited leading to a<br />prolonged half-life and prolonged ketamine-induced sleeping time. In the presence<br />of diazepam, a reduced ketamine concentration is required to achieve adequate<br />anaesthesia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />The safety of Valium for use in human pregnancy has not been established. An increased<br />risk of congenital malformation associated with the use of benzodiazepines during the<br />first trimester of pregnancy has been suggested.</p><p>Review of spontaneously reported adverse drug events shows no greater incidence than<br />would be anticipated from a similar untreated population. Benzodiazepines should be<br />avoided during pregnancy unless there is no safer alternative. Before administering<br />Valium during pregnancy, especially during the first trimester, possible risks for the<br />foetus should - as with any other drug - be weighed against the expected therapeutic<br />benefit for the mother.<br />Continuous administration of benzodiazepines during pregnancy may give rise to<br />hypotension, reduced respiratory function and hypothermia in the newborn child (see 5.2<br />Pharmacokinetics in Special Populations). Withdrawal symptoms in newborn infants<br />have occasionally been reported with this class of drugs.</p><p>Lactation</p><p>Since diazepam passes into breast milk, Valium should not be administered to breast-<br />feeding mothers.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sedation, amnesia, impaired concentration and impaired muscle function may adversely<br />affect the ability to drive or operate machinery. Prior to receiving Valium, the patient<br />should be warned not to drive a vehicle or operate a machine until completely recovered.<br />The physician should decide when these activities may be resumed.<br />If sleep duration is insufficient or alcohol is consumed, the likelihood of impaired<br />alertness may be increased. (see 4.9 Interactions with other Medicinal Products and other<br />Forms of Interaction).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General Disorders and Administration Site Conditions: Venous thrombosis, phlebitis,<br />injection site irritation, local swelling, or - less frequently &ndash; vascular changes may occur,<br />particularly after rapid i.v. injection.<br />Very small veins should not be selected for injection; in particular, intra-arterial injection<br />or extravasation must be strictly avoided.</p><p>I.m. injection can result in local pain, in some cases accompanied by injection site<br />erythema. Tenderness is relatively common.<br />Respiratory, Thoracic and Mediastinal Disorders: Cardiorespiratory depression may occur<br />if the Valium is administered rectally.<br />To reports any side effect(s):<br />&bull; Saudi Arabia:<br /> The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p><p>&bull; Other GCC States:<br /> Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms<br />Benzodiazepines commonly cause drowsiness, ataxia, dysarthria and nystagmus.<br />Overdose of Valium is seldom life-threatening if the drug is taken alone, but may<br />lead to areflexia, apnoea, hypotension, cardiorespiratory depression and coma.<br />Coma, if it occurs, usually lasts a few hours but it may be more protracted and<br />cyclical, particularly in elderly patients. Benzodiazepine respiratory depressant<br />effects are more serious in patients with respiratory disease.<br />Benzodiazepines increase the effects of other central nervous system depressants,<br />including alcohol .<br />Treatment<br />Monitor the patient&rsquo;s vital signs and institute supportive measures as indicated by the<br />patient&rsquo;s clinical state. In particular, patients may require symptomatic treatment for<br />cardiorespiratory effects or central nervous system effects.<br />Further absorption should be prevented using an appropriate method e.g. treatment within<br />1-2 hours with activated charcoal. If activated charcoal is used airway protection is<br />imperative for drowsy patients. In case of mixed ingestion gastric lavage may be<br />considered, however not as a routine measure<br />If CNS depression is severe consider the use of flumazenil (Anexate&reg;), a benzodiazepine<br />antagonist. This should only be administered under closely monitored conditions. It<br />has a short half-life (about an hour), therefore patients administered flumazenil will<br />require monitoring after its effects have worn off. Flumazenil is to be used with<br />extreme caution in the presence of drugs that reduce seizure threshold (e.g. tricyclic<br />antidepressants). Refer to the prescribing information for flumazenil (Anexate&reg;),<br />for further information on the correct use of this drug.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC code: N05BA01.<br />Mechanism of action and pharmacodynamics<br />Diazepam is a member of the group of benzodiazepine tranquilizers which exert<br />anxiolytic, sedative, muscle-relaxant, anticonvulsant and amnesic effects. Its action is<br />enhanced by generation of active metabolites (mainly desmethydiazepam). The central<br />actions of benzodiazepines are mediated through an enhancement of the GABAergic<br />neurotransmission at inhibitory synapses. In the presence of benzodiazepines, the affinity<br />of the GABA receptor for the neurotransmitter is enhanced through positive allosteric<br />modulation resulting in an increased action of released GABA on the postsynaptic<br />transmembrane chloride ion flux.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Diazepam is rapidly and completely absorbed from the gastrointestinal tract, peak plasma<br />concentrations appearing 30-90 minutes after oral ingestion.<br />On i.m. injection the extent of absorption is complete, The rate of absorption is variable<br />and depends on site and depth of the injection.<br />Following daily dosing, diazepam levels reach a steady state within approximately 5 days;<br />it takes about twice as long before desmethyl-diazepam levels reach a steady-state.<br />Average steady-state levels of diazepam after once daily administration are approximately<br />twice as high as the peak levels of the drug after the first dose.<br />During treatment, the elimination half-life of diazepam may increase by 50% due to a</p><p>reduction in hepatic clearance. Reports on the evolution of plasma levels during long-<br />term treatment are conflicting. A strong decrease of diazepam levels during long-term</p><p>treatment, possibly due to metabolic auto-induction, has been found, but in other studies<br />plasma concentrations of both diazepam and its desmethyl metabolite were independent<br />of duration of therapy<br />Distribution<br />Diazepam is widely distributed into tissues despite high binding to plasma proteins (98-<br />99%, mainly albumin and to lesser extent &alpha;1-acid glycoprotein. After intravenous<br />administration, a pronounced distribution phase is seen in plasma concentrations with a<br />half-life of distribution of up to 3 hours. The volume of distribution at steady state<br />averages between 0.88 and 1.1l/kg when derived from plasma concentration<br />measurements. Both protein binding and volume of distribution of desmethyl-diazepam<br />are similar to those of diazepam.<br />The high protein binding limits the extent of diazepam uptake into the cerebrospinal fluid<br />(CSF). CSF levels in man following single and multiple doses approximate closely the</p><p>free drug concentration in plasma. Upon multiple dosing desmethyl-diazepam, but not<br />diazepam, may significantly accumulate in CSF. Diazepam has very rapid uptake into and<br />equilibration with brain tissue, with equilibrium concentrations in brain exceeding those</p><p>in plasma. The overall time-course of receptor occupancy was consistent with the time-<br />course of the sum of brain concentrations of diazepam plus metabolites</p><p>Metabolism<br />Diazepam is mainly metabolized to pharmacologically active metabolites such as<br />desmethyldiazepam, a pathway accounting for 50-60% of total diazepam clearance; 3-<br />hydroxylation (27% of total diazepam clearance) is slow, leading to only low plasma<br />levels of the oxidation products temazepam and oxazepam. Oxazepam and temazepam<br />are further conjugated to glucuronides. After multiple doses of diazepam plasma<br />concentration ratios of desmethyl-diazepam/ diazepam were 1.1 &plusmn; 0.2, temazepam/<br />diazepam 0.11 &plusmn; 0.05, and oxazepam/ diazepam 0.09 &plusmn; 0.03 [103].<br />Oxidation of diazepam is mediated by cytochrome P450 isozymes; formation of<br />desmethyl-diazepam mainly by CYP2C19 and CYP3A and 3-hydroxy-diazepam<br />(temazepam) and oxazepam by CYP3A, Because CYP2C19 is polymorphic, extensive<br />metabolizers (EMs), and poor metabolizers (PMs) of diazepam can be distinguished. PMs<br />of diazepam showed significantly lower clearance (12 vs 26 mL/min) and longer<br />elimination half-life (88 vs 41 h) of diazepam than EMs after a single oral dose. Also,</p><p>PMs had lower clearance, higher AUC and longer elimination half-life of desmethyl-<br />diazepam. There appear to be inter-ethnic differences in this polymorphism.</p><p>Elimination<br />The plasma concentration-time decline of diazepam after administration is biphasic, an<br />initial rapid and extensive distribution phase being followed by a prolonged terminal<br />elimination phase. Typical elimination half-life values are in the range of 24-48 hours for<br />diazepam and 40-100 hours for the active metabolite desmethyldiazepam. The clearance<br />of diazepam is 20-40 ml/min.<br />Only insignificant amounts of unchanged diazepam are eliminated indicating that the<br />drug is almost completely metabolized before leaving the body;. Oxazepam-glucuronide<br />is the main drug-related product in urine.<br />Pharmacokinetics in special patient populations<br />Geriatric Population<br />The unbound fraction of diazepam correlates positively with age and was higher in</p><p>elderly than in young subjects. Age decreases the capacity of the liver for N-<br />demethylation and 3-hydroxylation of diazepam. An age-dependent decrease in clearance</p><p>of unbound drug occurs and is responsible for the observed 2-4 fold increase in<br />elimination half-life in the elderly, with a stronger effect seen in males than females.<br />Hence the extent of accumulation of unbound pharmacologically active diazepam in<br />elderly persons during multiple dosing will be greater than in younger adults.<br />The elimination of desmethyl-diazepam is slower in elderly males, but not in females.Hepatic impairment<br />Disposition of both diazepam and desmethyl-diazepam is altered in liver disease. In acute<br />viral hepatitis, the half-life of diazepam is increased by about 2-fold but returns slowly to<br />normal on recovery. A more marked (2- to 5-fold) increase in the elimination half-life is<br />seen in patients with alcoholic cirrhosis. These changes are primarily due to impaired<br />hepatic metabolism; altered distribution due to changes in protein binding may be<br />contributory. The reduced clearance of diazepam and desmethyl-diazepam leads to their<br />increased accumulation during long-term dosing. This in turn is associated with increased<br />sedation.<br />Renal impairment<br />In chronic renal failure, elimination of diazepam, as indicated by clearance of unbound<br />drug, was similar to that in healthy volunteers; thus steady-state concentrations of<br />unbound diazepam at any given daily dose on the average should not be different between<br />patients with renal insufficiency and healthy individuals. Due to changes in plasma<br />protein binding and tissue distribution of diazepam its elimination half-life was shortened<br />in renal disease from (mean &plusmn;S.E.) 92 &plusmn;23 h in control to 37 &plusmn;7 h in renal failure subjects.<br />Pregnancy<br />Diazepam and desmethyl-diazepam readily cross the placental barrier. The fetus can also<br />carry out N-demethylation of diazepam. Long-term treatment leads to accumulation of<br />both compounds in the fetus with high levels in the fetal heart, lungs and brain.<br />Plasma protein binding of diazepam is decreased during pregnancy, particularly during<br />the last trimester, partly due to the fall in serum albumin concentration. Increased<br />pharmacological effects may result after acute dosing. (see 4.6 Pregnancy)<br />Pediatric Population<br />During the first day of life, the free fractions of diazepam and desmethyl-diazepam<br />increased sharply to twice the values at birth and subsequently declined slowly to reach<br />near control values at one week of age. These changes parallel those of free fatty acid<br />concentrations.<br />Newborns and premature infants metabolize diazepam more slowly than older children<br />and adults leading to a prolonged half-life (very pronounced in premature newborns)<br />unless there was exposure to inducing agents before or immediately after birth. The<br />newborn&#39;s capacity to carry out metabolic processes involved in the biotransformation of<br />diazepam, including hydroxylation, demethylation, and glucuronide conjugation, remains<br />limited before 5 months of age; after this time hepatic enzymes develop to or even exceed<br />adult capacity.<br />Diazepam and its metabolites are excreted in breast milk. Concentrations of diazepam in<br />milk are only 10% of those in maternal blood. Normalized for body weight,<br />approximately 5% of the mother&rsquo;s dose reaches the baby. After multiple administrations<br />of more than 10 mg daily doses the amounts transferred may be large enough to show<br />effects in the baby. (see 4.6 Lactation).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carcinogenicity<br />The carcinogenic potential of oral diazepam has been studied in several rodent species.<br />An increase in the incidence of hepatocellular tumours occurred in male mice. No<br />significant increase in the incidence of tumours was observed in female mice, rats,<br />hamsters or gerbils.<br />Genotoxicity<br />A number of studies have provided weak evidence of a mutagenic potential at high<br />concentrations which are, however, far above therapeutic doses in humans.<br />Impaired fertility<br />Reproductive studies in rats showed decreases in the number of pregnancies and in the<br />number of surviving offspring following administration of oral doses of 100 mg/kg/day<br />prior to and during mating and throughout gestation and lactation.<br />Reproductive toxicity<br />Diazepam was found to be teratogenic in mice at dose levels of 45-50 mg/kg 100 mg/kg,<br />and 140 mg/kg/day as well as in hamsters at 280 mg/kg. In contrast, this drug was<br />shown to be non teratogenic at 80 and 300 mg/kg/day in rats and at 20 and 50<br />mg/kg/day in rabbits (see 4.6 Pregnancy).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Valium Ampoules, 10 mg/2 ml: preservative: 95 mg sodium benzoate (E211); 5 mg<br />benzoic acid (E210); benzyl alcohol, propylene glycol; ethyl alcohol; 2 ml water for<br />injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Valium Ampoules can be diluted with the following infusion solutions: Sodium Chloride<br />0.9%, Dextrose 5.5% or Dextrose 10%.<br />Chemically and physically in use stability has been demonstrated for 24 hours at room<br />temperature.<br />From a microbiological point of view the product should be used immediately. If not used<br />immediately, in-use storage times and conditions prior to use are the responsibility<br />of the user.<br />Use of PVC-containing infusion sets<br />Use of PVC-containing containers and infusion sets may result in decreased<br />concentrations of diazepam.<br />Disposal of unused/expired medicines</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The medicine should not be used after the expiry date (EXP) shown on the pack. The
contents must not be used if cloudy.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Valium ampoules, 10 mg/2 ml: Store below 30&deg;C and protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clear injection solution containing 10 mg diazepam per 2 ml in 1 vial pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The release of pharmaceuticals in the environment should be minimized. Medicines<br />should not be disposed of via wastewater and disposal through household waste should be<br />avoided. Use established &ldquo;collection systems&rdquo;, if available in your location.</p><p>Medicine: keep out of reach of children</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Made for F. Hoffmann-La Roche Ltd, Basel, Switzerland by CENEXI SAS, Fontenay-
sous-Bois, France

8. MARKETING AUTHORISATION NUMBER(S)
30 433 01
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
8/Mar/2010
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Current at: July 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>